Wall Street Analysts Are Bullish on Top Healthcare Picks
According to TipRanks.com, Livnat has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Verrica Pharmaceuticals with a $11.50 average price target.
See today’s best-performing stocks on TipRanks >>Mainz Biomed B.V. (MYNZ) H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Mainz Biomed B.V. today and set a price target of $25.00. The company's shares closed last Tuesday at $10.15, close to its 52-week low of $7.80.According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Mainz Biomed B.V. is a Moderate Buy with an average price target of $25.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on VRCA:- Aurora Mobile Brings JPush to Amazon Web Services Marketplace
- Fanhua Announces Completion of Distribution of CNFinance Shares
- Sugarbud Announces Shares for Services Arrangements
- Net Asset Value(s)
- Nordic American Tankers Ltd (NYSE: NAT) – Two suezmax newbuildings delivered and two long term contracts established
Paid Post: Content produced by TipRanks. The Globe and Mail was not involved, and material was not reviewed prior to publication.
